BIKAM and Dalton Medicinal Chemistry Expand and Renew Research Agreement

30-Oct-2009 - USA

Bikam and Dalton medicinal chemistry have jointly announced a renewal of their exclusive worldwide collaboration and agreement to discover and develop new ophthalmology therapeutics.

Dalton Medicinal Chemistry will continue to utilize their proprietary insights to advance several novel classes of compounds against selected BIKAM targets. BIKAM will advance these agents with their growing cutting edge battery of biological assays and delivery methodologies.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances